Sun Yat-sen University

Company snapshot

Sun Yat-sen University, originally known as Guangdong University, was founded in 1924 by Dr. Sun Yat-sen (also called Sun Zhongshan), a great democratic revolutionary leader of the 20th century. The University is located in Guangdong Province, an area neighboring Hong Kong and Macao, which is at the forefront of China’s reform and opening up. Being one of the leading universities in the People’s R

• 19 active pipeline program(s) linked via ClinicalTrials.gov.
• 19 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sun Yat-sen University. Not investment advice.

• Peer + 0 momentum

  Hospital Authority

  TA overlap score 40

• Peer + 0 momentum

  Chinese Academy of

  TA overlap score 40

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Sun Yat-sen University.

1. Jun 8, 2026 Clinical update

   TPC induction chemotherapy — Phase 2

2. Jun 8, 2026 Clinical update

   Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine — Phase 2

3. Jun 8, 2026 Clinical update

   postoperative antimicrobial prophylaxis — Phase 3

4. Jun 8, 2026 Clinical update

   Palliative Chemotherapy — Phase 3

5. Jun 8, 2026 Clinical update

   gemcitabine and cisplatin (Induction chemotherapy) — Phase 3

View all clinical trial activity →

• What is Sun Yat-sen University?

  Sun Yat-sen University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Safety of Almonertinib, Subjects With Hyperuricemia, Renal Function Disorder, Acute-On-Chronic Liver Failure. NovaPharmaNews links 19 clinical pr

• Is Sun Yat-sen University publicly traded?

  Sun Yat-sen University appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Sun Yat-sen University develop or market?

  We link 25 drug profile(s) where Sun Yat-sen University is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sun-yat-sen-university#company-drugs.

• What are the latest developments for Sun Yat-sen University?

  In the last 12 months our linked public records show 19 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Sun Yat-sen University focus on?

  Sun Yat-sen University focuses on Nasopharyngeal Carcinoma, Safety of Almonertinib, Subjects With Hyperuricemia based on our analysis of their pipeline programs and drug development activities.